$Relmada Therapeutics (RLMD.US)$$Denali Therapeutics (DNLI.U...

$Relmada Therapeutics (RLMD.US)$ $Denali Therapeutics (DNLI.US)$ $Tango Therapeutics (TNGX.US)$ $Goldman Sachs (GS.US)$ Goldman Sachs announced the latest list of potential acquisitions in the biopharmaceutical sector. Relmada, Denali and Tango have the most potential acquisition opportunities of the nine newly listed companies, Goldman sachs said. Relmada could trade at $115 a share, a 512% premium to its current price; Denali could trade at $166 a share, a 283% premium to its current price; Tango is likely to trade at $43.40 a share, a 295% premium to its current share price. The health care company with the biggest premium of the 24 companies listed is $uniQure NV (QURE.US)$, which Goldman estimates could trade at $174 a share, a 516% premium to its current price.